N-butyl-N-propylaniline

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: N-butyl-N-propylaniline
• 英文别名: N-Butyl-N-propyl-anilin
• 化学式: C₁₃H₂₁N
• 分子量: 191.316
• InChiKey: QREKQQXDZILMEW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  14
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  3.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为产物：
  描述：

  N-butyl-N-propylhydroxylamine 在 三乙胺 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 环己烷 为溶剂， 生成 N-butyl-N-propylaniline
  参考文献：
  名称：

  流动化学的功能性有机锂试剂无催化剂胺化

  摘要：

  报告的是在温和的反应条件下，使用流动微反应器，通过精心设计的胺化试剂，对功能性有机锂中间体进行了亲电胺化反应。胺化试剂经过优化，可在不使用任何催化剂的情况下实现有效的CN键形成。通过使用流动微反应器，在温和的反应条件下，在1分钟内成功进行了官能化芳基锂的亲电子胺化反应。胺化试剂也通过流动方法制备。根据停止流NMR分析，快速优化了制备胺化试剂的反应时间，而无需进行后处理。集成的单流合成，包括芳基锂的生成，胺化试剂的制备，

  DOI：

  10.1002/anie.201713031

文献信息

• PREPARATION AND METHOD FOR USE IN THE TREATMENT OF RESPIRATORY DISEASES
  申请人：UNIVERSITE LAVAL

  公开号：US20160046587A1

  公开（公告）日：2016-02-18

  The present disclosure relates to a novel active compound having the formula Ia: solid preparations, uses and methods for the treatment or prevention of respiratory diseases comprising said compound as well as process of preparation thereof.

  本公开涉及一种具有Ia式的新型活性化合物：固体制剂，以及包括该化合物的用于治疗或预防呼吸系统疾病的方法和过程的制备。
• PHOTOELECTRIC CONVERSION ELEMENT, DYE-SENSITIZED SOLAR CELL, METAL COMPLEX DYE, DYE SOLUTION, AND OXIDE SEMICONDUCTOR ELECTRODE
  申请人：FUJIFILM Corporation

  公开号：EP3522191A1

  公开（公告）日：2019-08-07

  Provided are a photoelectric conversion element including an electrically conductive support, a photoconductor layer including an electrolyte, a charge transfer layer including an electrolyte, and a counter electrode. The photoconductor layer has semiconductor fine particles having a metal complex dye represented by specific Formula (1) supported thereon; a dye-sensitized solar cell; a metal complex dye; a dye solution; and an oxide semiconductor electrode.

  提供了一种光电转换元件，包括导电支架、包括电解质的光电导层、包括电解质的电荷转移层和对电极。光电导体层上有半导体微粒，微粒上有由具体式（1）表示的金属络合染料；染料敏化太阳能电池；金属络合染料；染料溶液；以及氧化物半导体电极。
• PRODUCTION METHOD FOR RADIATION-SENSITIVE RESIN COMPOSITION
  申请人：FUJIFILM Corporation

  公开号：EP3992713A1

  公开（公告）日：2022-05-04

  Provided is a method for producing a radiation-sensitive resin composition, in which the occurrence of defects in a pattern thus formed is suppressed and a fluctuation in a sensitivity after long-term storage is suppressed. The method for producing a radiation-sensitive resin composition includes a step 1 of putting at least a resin having a polarity that increases by an action of an acid, a photoacid generator, and a solvent into a stirring tank, and a step 2 of producing a radiation-sensitive resin composition by stirring and mixing the resin having a polarity that increases by the action of an acid, the photoacid generator, and the solvent in the stirring tank under a gas having an inert gas concentration of 90% by volume or more, in which in the step 2, an atmospheric pressure inside the stirring tank is higher than an atmospheric pressure outside the stirring tank, and in the step 2, a difference between the atmospheric pressure inside the stirring tank and the atmospheric pressure outside the stirring tank is 2.0 kPa or less.

  本发明提供了一种生产辐射敏感树脂组合物的方法，该方法可抑制由此形成的图案中出现缺陷，并可抑制长期储存后的灵敏度波动。生产辐射敏感树脂组合物的方法包括步骤 1：将至少一种在酸的作用下极性增强的树脂、光酸发生器和溶剂放入搅拌罐中；步骤 2：通过在搅拌罐中搅拌和混合在酸的作用下极性增强的树脂、光酸发生器和溶剂，生产辐射敏感树脂组合物、在惰性气体浓度为 90% （体积比）或更高的气体下，在搅拌罐中搅拌并混合具有极性的树脂、光酸发生器和溶剂，其中在步骤 2 中，搅拌罐内的大气压力高于搅拌罐外的大气压力，并且在步骤 2 中，搅拌罐内的大气压力与搅拌罐外的大气压力之差为 2.0 千帕或更小。
• Chemotherapeutic Dyes. III. 5-Heterocyclicamino-9-dialkylaminobenzo [a]phenoxazines¹
  作者：Moses L. Crossley、Corris M. Hofmann、Paul F. Dreisbach

  DOI：10.1021/ja01123a003

  日期：1952.2
• Compounds Having Activity in Increasing Ion Transport by Mutant-Cftr and Uses Thereof
  申请人：Verkman Alan

  公开号：US20080319008A1

  公开（公告）日：2008-12-25

  The invention provides compositions, pharmaceutical preparations and methods for increasing activity (e.g., ion transport) of the mutant cystic fibrosis transmembrane conductance regulator protein (mutant-CFTR), e.g., ΔF508 CFTR, G551D-CFTR, G1349D-CFTR, or D1152H-CFTR, that are useful for the treatment of cystic fibrosis (CF). The compositions and pharmaceutical preparations of the invention may comprise one or more phenylglycine-containing compounds or sulfonamide-containing compounds of the invention, or an analog or derivative thereof.